Buy Bulk IPAMORELIN 2000mcg (Save Up to 85%)

IPAMORELIN 2000mcg is a synthetic peptide that belongs to the family of growth hormone-releasing peptides (GHRPs). It is known for its ability to stimulate the secretion of growth hormone and insulin-like growth factor-1 (IGF-1) in a dose-dependent manner. Due to its potent growth-promoting effects, ipamorelin has been widely used in research studies in both in vitro and non-clinical models.

One study investigated the potential of ipamorelin to stimulate the release of growth hormone from primary rat pituitary cells in vitro. Ipamorelin caused the release of growth hormone in pentobarbital-anesthetized rats as well as in conscious swine. Surprisingly, it was observed that even at doses over 200 times higher than the effective dose for growth hormone release, ipamorelin did not significantly stimulate the release of adrenocorticotropic hormone (ACTH) or cortisol in plasma when compared to the levels induced by growth hormone-releasing (GHRH) stimulation. The absence of an effect on ACTH and cortisol suggests a selective mechanism of action for ipamorelin in stimulating growth hormone release. ⁽¹⁾

Ipamorelin has been used in several non-clinical studies to investigate its effects on growth and body composition in animal models. One study investigated the effects of chronic ipamorelin treatment on the growth of rats. The results showed that Ipamorelin significantly increased body weight and bone length in the treated rats compared to the control group.  ^(2,3) 

A nine-week study was conducted on female mice with and without growth hormone deficiency to compare the effects of ipamorelin and human growth hormone on weight gain and adiposity. The mice received twice-daily injections of either ipamorelin, human growth hormone, or 0.9% saline to assess the differential impact of these compounds. Results showed that ipamorelin treatment led to less weight gain compared to growth hormone treatment, with growth hormone-deficient mice gaining 15.3% and 95.5% in ipamorelin and growth hormone-treated mice, respectively. Non-growth hormone-deficient mice showed similar results, with ipamorelin leading to 16.9% weight gain and GH leading to 27.5% weight gain. Notably, ipamorelin did not lead to changes in relative organ weight, while growth hormone treatment resulted in increased liver weight, suggesting that ipamorelin may not produce the same organomegaly as growth hormone treatment. ⁽⁴⁾

It's important to note that while ipamorelin has shown promise in preclinical and clinical studies, more research is needed to establish its safety and efficacy in humans. Additionally, ipamorelin is currently not approved for human use by regulatory agencies such as the FDA and is only available for research purposes.

References: 1. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-561. 2. Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histol Histopathol. 2002;17(3):707-714. 3. Svensson J et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-577. 4. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001 Jan 12;280(1):132-138.